NasdaqGM:NNNNBiotechs
Anbio Biotechnology (ANBF) Non Cash 74.1% Net Margin Fuels Fresh Debate On Earnings Quality
Anbio Biotechnology (ANBF) has reported its FY 2025 results, with first half revenue of US$4.6 million and basic EPS of US$0.09. This is set against a trailing twelve month revenue base of US$8.6 million and EPS of US$0.15 that is linked to a 169.9% earnings increase over the past year. Over recent periods the company has seen revenue move from US$5.8 million in 1H 2024 to US$2.3 million in 2H 2024 and then to US$4.6 million in 1H 2025, while net income shifted from US$3.6 million to a US$1.2...